References
- Pikor LA , BellJC, DialloJS . Oncolytic viruses: exploiting cancer’s deal with the devil . Trends Cancer1 ( 4 ), 266 – 277 ( 2015 ).
- Lichty BD , BreitbachCJ, StojdlDF, BellJC . Going viral with cancer immunotherapy . Nat. Rev. Cancer14 ( 8 ), 559 – 567 ( 2014 ).
- Berkey SE , ThorneSH, BartlettDL . Oncolytic virotherapy and the tumor microenvironment . Adv. Exp. Med. Biol.1036, 157 – 172 ( 2017 ).
- Deng L , FanJ, DingYet al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9 . Oncotarget8 ( 25 ), 40533 – 40543 ( 2017 ).
- Quan B , SeoHS, BlobelG, RenY . Vesiculoviral matrix (M) protein occupies nucleic acid binding site at nucleoporin pair (Rae1 * Nup98) . Proc. Natl Acad. Sci. USA111 ( 25 ), 9127 – 9132 ( 2014 ).
- Li X , WangP, LiHet al. The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in Syrian Hamster Model . Clin. Cancer Res.23 ( 1 ), 239 – 249 ( 2017 ).
- Su C , ZhanG, ZhengC . Evasion of host antiviral innate immunity by HSV-1, an update . Virol. J.13, 38 ( 2016 ).
- Heinrich B , KleinJ, DelicMet al. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes . Onco Targets Ther.10, 2389 – 2401 ( 2017 ).
- Kouidhi S , Ben AyedF, Benammar ElgaaiedA . Targeting tumor metabolism: a new challenge to improve immunotherapy . Front. Immunol.9, 353 ( 2018 ).
- Wang P , LiX, WangJet al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent . Nat. Commun.8 ( 1 ), 1395 ( 2017 ).
- Martinez-Reza I , DiazL, Garcia-BecerraR . Preclinical and clinical aspects of TNF-alpha and its receptors TNFR1 and TNFR2 in breast cancer . J. Biomed. Sci.24 ( 1 ), 90 ( 2017 ).
- Bommareddy PK , PatelA, HossainS, KaufmanHL . Talimogene Laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma . Am. J. Clin. Dermatol.18 ( 1 ), 1 – 15 ( 2017 ).
- Jiang H , Rivera-MolinaY, Gomez-ManzanoCet al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination . Cancer Res.77 ( 14 ), 3894 – 3907 ( 2017 ).
- Sagiv-Barfi I , CzerwinskiDK, LevySet al. Eradication of spontaneous malignancy by local immunotherapy . Sci. Transl. Med.10 ( 426 ), pii:eaan4488 ( 2018 ).
- Knee DA , HewesB, BrogdonJL . Rationale for anti-GITR cancer immunotherapy . Eur. J. Cancer67, 1 – 10 ( 2016 ).
- Zamarin D , HolmgaardRB, RiccaJet al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity . Nat. Commun.8, 14340 ( 2017 ).
- Chen S , LeeLF, FisherTSet al. Combination of 4–1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model . Cancer Immunol. Res.3 ( 2 ), 149 – 160 ( 2015 ).
- Scott EM , DuffyMR, FreedmanJD, FisherKD, SeymourLW . Solid tumor immunotherapy with T Cell engager-armed oncolytic viruses . Macromol. Biosci.18 ( 1 ), doi:10.1002/mabi.201700187 ( 2018 ).
- Topalian SL , DrakeCG, PardollDM . Immune checkpoint blockade: a common denominator approach to cancer therapy . Cancer Cell27 ( 4 ), 450 – 461 ( 2015 ).
- Bourgeois-Daigneault MC , RoyDG, AitkenASet al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy . Sci. Transl. Med.10 ( 422 ), pii:eaao1641 ( 2018 ).
- Ribas A , DummerR, PuzanovIet al. Oncolytic virotherapy promotes intratumoral T Cell infiltration and improves anti-PD-1 immunotherapy . Cell170 ( 6 ), 1109e1110 – 1119e1110 ( 2017 ).
- Samson A , ScottKJ, TaggartDet al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade . Sci. Transl. Med.10 ( 422 ), pii:eaam7577 ( 2018 ).
- Kleinpeter P , FendL, ThioudelletCet al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition . Oncoimmunology5 ( 10 ), e1220467 ( 2016 ).
- Hamilton JR , VijayakumarG, PaleseP . A recombinant antibody-expressing influenza virus delays tumor growth in a mouse model . Cell Rep.22 ( 1 ), 1 – 7 ( 2018 ).
- Bartee MY , DunlapKM, BarteeE . Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy . Cancer Res.77 ( 11 ), 2952 – 2963 ( 2017 ).